UCB (OTCMKTS:UCBJF) Shares Gap Down – Time to Sell?

UCB SA (OTCMKTS:UCBJF) gapped down before the market opened on Thursday . The stock had previously closed at $280.4875, but opened at $259.59. UCB shares last traded at $259.59, with a volume of 50 shares traded.

Analysts Set New Price Targets

Separately, Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, UCB presently has an average rating of “Moderate Buy”.

UCB Stock Down 12.2%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The stock has a 50 day moving average of $292.81 and a 200 day moving average of $300.57.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.